Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. / Phillips, Andrew N; Cambiano, Valentina; Miners, Alec; Lampe, Fiona C; Rodger, Alison; Nakagawa, Fumiyo; Brown, Alison; Gill, O Noel; De Angelis, Daniela; Elford, Jonathan; Hart, Graham; Johnson, Anne M; Lundgren, Jens D; Collins, Simon; Delpech, Valerie.

In: AIDS (London, England), Vol. 29, No. 14, 10.09.2015, p. 1855-62.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Phillips, AN, Cambiano, V, Miners, A, Lampe, FC, Rodger, A, Nakagawa, F, Brown, A, Gill, ON, De Angelis, D, Elford, J, Hart, G, Johnson, AM, Lundgren, JD, Collins, S & Delpech, V 2015, 'Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM', AIDS (London, England), vol. 29, no. 14, pp. 1855-62. https://doi.org/10.1097/QAD.0000000000000767

APA

Phillips, A. N., Cambiano, V., Miners, A., Lampe, F. C., Rodger, A., Nakagawa, F., Brown, A., Gill, O. N., De Angelis, D., Elford, J., Hart, G., Johnson, A. M., Lundgren, J. D., Collins, S., & Delpech, V. (2015). Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS (London, England), 29(14), 1855-62. https://doi.org/10.1097/QAD.0000000000000767

Vancouver

Phillips AN, Cambiano V, Miners A, Lampe FC, Rodger A, Nakagawa F et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS (London, England). 2015 Sep 10;29(14):1855-62. https://doi.org/10.1097/QAD.0000000000000767

Author

Phillips, Andrew N ; Cambiano, Valentina ; Miners, Alec ; Lampe, Fiona C ; Rodger, Alison ; Nakagawa, Fumiyo ; Brown, Alison ; Gill, O Noel ; De Angelis, Daniela ; Elford, Jonathan ; Hart, Graham ; Johnson, Anne M ; Lundgren, Jens D ; Collins, Simon ; Delpech, Valerie. / Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. In: AIDS (London, England). 2015 ; Vol. 29, No. 14. pp. 1855-62.

Bibtex

@article{6de8a7ac3c234e68bcfc241a2ed8d641,
title = "Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM",
abstract = "BACKGROUND: Increased rates of testing, with early antiretroviral therapy (ART) initiation, represent a key potential HIV-prevention approach. Currently, in MSM in the United Kingdom, it is estimated that 36% are diagnosed by 1 year from infection, and the ART initiation threshold is at CD4 cell count 350/μl. We investigated what would be required to reduce HIV incidence in MSM to below 1 per 1000 person-years (i.e. <535 new infections per year) by 2030, and whether this is likely to be cost-effective.METHODS: A dynamic, individual-based simulation model was calibrated to multiple data sources on HIV in MSM in the United Kingdom. Outcomes were projected according to future alternative HIV testing and ART initiation scenarios to 2030, considering also potential changes in levels of condomless sex.RESULTS: For ART use to result in an incidence of close to 1/1000 person-years requires the proportion of all HIV-positive MSM with viral suppression to increase from below 60% currently to 90%, assuming no rise in levels of condomless sex. Substantial increases in HIV testing, such that over 90% of men are diagnosed within a year of infection, would increase the proportion of HIV-positive men with viral suppression to 80%, and it would be 90%, if ART is initiated at diagnosis. The scenarios required for such a policy to be cost-effective are presented.CONCLUSION: This analysis provides targets for the proportion of all HIV-positive MSM with viral suppression required to achieve substantial reductions in HIV incidence.",
author = "Phillips, {Andrew N} and Valentina Cambiano and Alec Miners and Lampe, {Fiona C} and Alison Rodger and Fumiyo Nakagawa and Alison Brown and Gill, {O Noel} and {De Angelis}, Daniela and Jonathan Elford and Graham Hart and Johnson, {Anne M} and Lundgren, {Jens D} and Simon Collins and Valerie Delpech",
year = "2015",
month = sep,
day = "10",
doi = "10.1097/QAD.0000000000000767",
language = "English",
volume = "29",
pages = "1855--62",
journal = "AIDS",
issn = "1350-2840",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "14",

}

RIS

TY - JOUR

T1 - Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM

AU - Phillips, Andrew N

AU - Cambiano, Valentina

AU - Miners, Alec

AU - Lampe, Fiona C

AU - Rodger, Alison

AU - Nakagawa, Fumiyo

AU - Brown, Alison

AU - Gill, O Noel

AU - De Angelis, Daniela

AU - Elford, Jonathan

AU - Hart, Graham

AU - Johnson, Anne M

AU - Lundgren, Jens D

AU - Collins, Simon

AU - Delpech, Valerie

PY - 2015/9/10

Y1 - 2015/9/10

N2 - BACKGROUND: Increased rates of testing, with early antiretroviral therapy (ART) initiation, represent a key potential HIV-prevention approach. Currently, in MSM in the United Kingdom, it is estimated that 36% are diagnosed by 1 year from infection, and the ART initiation threshold is at CD4 cell count 350/μl. We investigated what would be required to reduce HIV incidence in MSM to below 1 per 1000 person-years (i.e. <535 new infections per year) by 2030, and whether this is likely to be cost-effective.METHODS: A dynamic, individual-based simulation model was calibrated to multiple data sources on HIV in MSM in the United Kingdom. Outcomes were projected according to future alternative HIV testing and ART initiation scenarios to 2030, considering also potential changes in levels of condomless sex.RESULTS: For ART use to result in an incidence of close to 1/1000 person-years requires the proportion of all HIV-positive MSM with viral suppression to increase from below 60% currently to 90%, assuming no rise in levels of condomless sex. Substantial increases in HIV testing, such that over 90% of men are diagnosed within a year of infection, would increase the proportion of HIV-positive men with viral suppression to 80%, and it would be 90%, if ART is initiated at diagnosis. The scenarios required for such a policy to be cost-effective are presented.CONCLUSION: This analysis provides targets for the proportion of all HIV-positive MSM with viral suppression required to achieve substantial reductions in HIV incidence.

AB - BACKGROUND: Increased rates of testing, with early antiretroviral therapy (ART) initiation, represent a key potential HIV-prevention approach. Currently, in MSM in the United Kingdom, it is estimated that 36% are diagnosed by 1 year from infection, and the ART initiation threshold is at CD4 cell count 350/μl. We investigated what would be required to reduce HIV incidence in MSM to below 1 per 1000 person-years (i.e. <535 new infections per year) by 2030, and whether this is likely to be cost-effective.METHODS: A dynamic, individual-based simulation model was calibrated to multiple data sources on HIV in MSM in the United Kingdom. Outcomes were projected according to future alternative HIV testing and ART initiation scenarios to 2030, considering also potential changes in levels of condomless sex.RESULTS: For ART use to result in an incidence of close to 1/1000 person-years requires the proportion of all HIV-positive MSM with viral suppression to increase from below 60% currently to 90%, assuming no rise in levels of condomless sex. Substantial increases in HIV testing, such that over 90% of men are diagnosed within a year of infection, would increase the proportion of HIV-positive men with viral suppression to 80%, and it would be 90%, if ART is initiated at diagnosis. The scenarios required for such a policy to be cost-effective are presented.CONCLUSION: This analysis provides targets for the proportion of all HIV-positive MSM with viral suppression required to achieve substantial reductions in HIV incidence.

U2 - 10.1097/QAD.0000000000000767

DO - 10.1097/QAD.0000000000000767

M3 - Journal article

C2 - 26372391

VL - 29

SP - 1855

EP - 1862

JO - AIDS

JF - AIDS

SN - 1350-2840

IS - 14

ER -

ID: 161700460